HC Wainwright Cuts MetaVia (NASDAQ:MTVA) Price Target to $20.00

MetaVia (NASDAQ:MTVA) had its price target lowered by HC Wainwright from $40.00 to $20.00 in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other research firms also recently commented on MTVA. Wall Street Zen downgraded shares of MetaVia from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $26.50.

MetaVia Price Performance

Shares of NASDAQ MTVA opened at $1.22 on Friday. The stock’s fifty day moving average price is $1.81 and its two-hundred day moving average price is $6.79. MetaVia has a one year low of $1.21 and a one year high of $23.10. The firm has a market cap of $2.68 million, a price-to-earnings ratio of -0.15 and a beta of 0.34.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC raised its position in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,386 shares of the company’s stock after purchasing an additional 18,506 shares during the period. SG Americas Securities LLC owned approximately 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. 1.37% of the stock is owned by institutional investors.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.